Delivery Order SPE2DB22D1017-SPE2DB24FF4VW
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Envarsus XR 1 mg tablets, with a ceiling value of $1,941.75 and a performance period through July 28, 2025. The contract is a firm-fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Envarsus XR 1 mg tablets, a pharmaceutical product. The contract has a ceiling value of $1,288.86 and a performance period extending through May 28, 2025. It is a firm-fixed-price delivery order contract, with no set-aside designation, indicating open competition. AmerisourceBergen...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company. The contract is for the supply of Envarsus XR 1 mg tablets, with a potential value of $1,216.11 and a period of performance through March 7, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Envarsus XR 4 mg tablets, a specialty medication, with a ceiling value of $3,230.68 and a period of performance through October 7, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The order, valued at $1,615.33, is for the supply of the specialty medication Envarsus XR 4 mg tablet 100s. The delivery order has an ultimate completion date of April 8, 2024 and is not associated with any set-aside designations. Amerisourcebergen Drug Corp serves as a prime...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,711.95, is for the delivery of Envarsus XR 4 mg tablets over a performance period ending on May 29, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Envarsus XR 1 mg tablets. The $2,577.72 firm-fixed-price contract has an ultimate completion date of April 3, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a broad range of pharmaceutical products and medical supplies...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, a firm fixed price delivery order contract valued at $1,465.68 for the supply of Envarsus XR 1 mg tablets. This order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary vehicle for...
- This federal contract award, valued at $1,621.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, for the delivery of Envarsus XR 1 mg tablets. The contract is a firm fixed price delivery order with an ultimate completion date of April 5, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Envarsus XR 4 mg tablets, a prescription medication. The contract has a ceiling value of $1,711.95 and a period of performance through July 9, 2025. This is a firm-fixed-price delivery order contract without a set-aside designation, indicating open competition....
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB24FF4VWDelivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract is for the provision of the pharmaceutical drug Envarsus XR 4 mg tablets, with a firm fixed price ceiling value of $6,461.32 and a period of performance through April 15, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical and medical products and supplies to support U.S. Department of Defense medical treatment programs and facilities worldwide. This latest delivery order award is issued against that overarching IDC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 3/25/24 |